Archive - FutureFemHealth Pro
FutureFemHealth Pro is built to help you understand what’s happening in women’s health and what it means.
Explore our FutureFemHealth Pro archive below - new pieces drop on Fridays.
Not yet part of FutureFemHealth Pro? Upgrade here.
The peptide precedent: what women’s health should really be watching
The interesting thing about peptides is the decisions they are forcing women's health platforms to make.
When women's health stops looking like women's health
What if the greatest success of women’s health is that it eventually stops looking like a separate market?
H1 2026 M&A Analysis: what this year’s deals tell us about the future of women’s health
Who is buying women's health? And what those transactions reveal about where the sector is heading. Access our analysis of all 33 deals from H1 2026 along with a downloadable tracker of each deal.
Q2 2026: women's health funding in review
We've tracked every women’s health funding round we've been able to verify globally. Access the analysis of 40 funding rounds and a downloadable tracker of each deal.
Beyond the prescription: The GLP-1 support economy in women’s health
GLP-1s are creating a support economy around everything that happens after the prescription, and women may be the most important customer group within it.
What actually counts as continuous hormone monitoring? Why the industry can’t agree
Continuous hormone monitoring is one of the most talked about emerging areas in women’s health.
What it takes to get reimbursed in women’s health - the Hello Inside story
Getting a women’s health product reimbursed through a public healthcare system can take years - if at all.
The messy middle of equity and inclusion in femtech
Can femtech scale without serving affluent women first?
How urinary incontinence became a real healthcare market
Urinary incontinence is a major chronic health category with significant unmet need, specialist shortages and long-term quality-of-life impacts. But recent breakthroughs in capital allocation and awareness of the need may not be simply down to better devices or therapies. Something more fundamental may be shifting.
Why women’s health is building a new ‘trust layer’
A new “trust layer” is emerging across women’s health.
Is Organon’s acquisition good for women’s health - or just good business?
When Organon was spun out of Merck & Co. in 2021, it stood out as one of the few scaled pharmaceutical companies built explicitly around women’s health.
Why the bone health market is moving earlier
A woman in her early 60s slips, falls, and breaks her hip. Within a year, there’s a one in five chance she won’t survive.
Q1 funding: what $1.24b into women’s health really tells us
Explore Q1 funding in women's health and download our tracker capturing every investment.
The PCOS opportunity: a deep dive into this unsolved area of women’s health
After more than a decade of campaigning work Polycystic Ovary Syndrome has been renamed to PMOS. Ahead of that, we published a deep dive into the category and the emerging innovation in the space.
Menstrual blood diagnostics in 2026: what's changing - and what we're tracking
For years, small groups of determined researchers, clinicians and founders have been working to destigmatise and normalise menstrual blood as a source of usable health data.